“Purpose of reviewAnthracyclines have markedly improved th


“Purpose of reviewAnthracyclines have markedly improved the survival rates of children with cancer. However, anthracycline-related cardiotoxicity is also Fludarabinum well recognized and can compromise the long-term outcome in some patients. The challenge remains of how to balance the chemotherapeutic effects of anthracycline treatment with its potentially serious cardiovascular complications. Here, we review the pathophysiology,

risk factors, clinical manifestations, prevention, and treatment of anthracycline-related cardiotoxicity.Recent findingsSome risk factors and biomarkers associated with an increased probability of anthracycline-related cardiotoxicity have been identified. Modifying the structural forms and dosages of anthracyclines and coadministering cardioprotective agents may prevent some of these cardiotoxic effects. Cardiovascular complications have also been treated with angiotensin-converting enzyme inhibitors, -blockers, and growth hormone replacement therapy. Cardiac transplantation remains the treatment of last Selleckchem LY2090314 resort.SummaryDespite major advances in

cancer treatment, anthracycline-related cardiotoxicity remains a major cause of morbidity and mortality in survivors of childhood cancer. Promising areas of research include: use of biomarkers for early recognition of cardiac injury in children receiving chemotherapy, development and application of cardioprotective agents for prevention of cardiotoxicity, and advancements in therapies for cardiac dysfunction in children after anthracycline treatment.”
“Automated technologies have revolutionised the monitoring of coagulation disorders in the central hospital laboratory setting, allowing for high throughput testing, improved accuracy and precision, accompanied by a marked reduction in human error. However, they still require trained operators and sample transportation. With the advent of point of care (POC) testing, the working principle of traditional coagulometers was used as the foundation for

the development of miniaturised devices. A number of POC coagulation devices have been commercially available Flavopiridol for many years now, allowing the patient to assume more control over the management of their own medication, e.g. warfarin. While POC devices for measuring anticoagulation have relied principally on clotting time tests, novel platelet function tests, and factor-specific assays based on enzymatic or immunoassay principles are becoming available, driven by the emergence of new anticoagulant drugs, in addition to the inability of clotting tests to accurately detect many thrombotic disorders. This review highlights recent progress in the development of POC coagulation monitoring technologies and examines their future potential in clinical diagnostics. (C) 2013 Elsevier Ltd. All rights reserved.”
“Therapeutic importance and benefices caused by antineoplastic drugs are unquestionable however unfortunately well-known are their side effects.

Comments are closed.